VoICE Immunization Evidence: Return on investment

Key Concept

Key Evidence: A series of studies in the U.S. estimated that the average savings in direct healthcare costs from rotavirus and acute gastroenteritis were between $121 million and $231 million per year once rotavirus vaccines were introduced.

Pindyck T, Tate JE, Parashar UD 2018. A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact. Expert Review of Vaccines. 17(7).

View Source >

Key Evidence: Vaccinating children against rotavirus in Bangladesh would prevent more than 50,000 outpatient visits and 40,000 hospitalizations in children under five each year, and reduce treatment costs by US$5.8 million over 2 years — nearly all (96%) from fewer hospitalizations. Since this study didn’t take herd effects into account, the actual impact would likely be greater.

Sarker AR, Sultana M, Mahumud RA, Van Der Meer R, Morton A. 2018. Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh. Human Vaccines & Immunotherapeutics. 14(1).

View Source >

Key Evidence: In a UK cost-effectiveness analysis, which takes into account herd effect, the budget impact analysis demonstrated that the introduction of a rotavirus vaccine (RVV) program could pay back between 58-96% of the cost outlay for the program within the first 4 years.

Atkins, K.E., Carroll, S., et al. 2012. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.. Vaccine. 30(48), 6766.

View Source >

Key Evidence: In an economic evaluation of vaccination against rotavirus conducted in Italy, it was shown that as early as the second year after rotavirus vaccine introduction, the vaccine cost would be more than offset by savings from prevention of disease cases and hospitalizations.

Carroll, S., GarcĂ­a Rojas, A. J., et al. 2015. Vaccination: short- to long-term benefits from investment. Market Access & Health Policy. 3: 27279.

View Source >